Clinical Trial

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-09-30; most recent amendment 2025-09-25.
Status change: Not Yet Recruiting → Recruiting 2025-04-22
Trial Details
NCT Number NCT06623136
Lead Sponsor Elpiscience (Suzhou) Biopharma, Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 40 participants
Start Date 2025-04-30
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-26